Status:
COMPLETED
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
Lead Sponsor:
AbbVie
Conditions:
Open-Angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (...
Eligibility Criteria
Inclusion
- \- Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment.
Exclusion
- Concurrent or anticipated enrollment in another investigational drug or device study or participation in such a study within 2 months prior to enrolling in this study.
- Previous administration with Bimatoprost SR in the study eye.
Key Trial Info
Start Date :
February 28 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 8 2025
Estimated Enrollment :
515 Patients enrolled
Trial Details
Trial ID
NCT03850782
Start Date
February 28 2019
End Date
August 8 2025
Last Update
August 19 2025
Active Locations (108)
Enter a location and click search to find clinical trials sorted by distance.
1
Horizon Eye Specialists & Lasik Centers /ID# 235240
Sun City, Arizona, United States, 85351
2
Atlantis Eye Care /ID# 235530
Huntington Beach, California, United States, 92647
3
Lakeside Vision Center /ID# 234970
Irvine, California, United States, 92604
4
Global Research Foundation /ID# 237350
Los Angeles, California, United States, 90041-1718